0000899243-19-003485.txt : 20190213 0000899243-19-003485.hdr.sgml : 20190213 20190213182059 ACCESSION NUMBER: 0000899243-19-003485 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190213 FILED AS OF DATE: 20190213 DATE AS OF CHANGE: 20190213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gibson Neil W CENTRAL INDEX KEY: 0001555918 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38811 FILM NUMBER: 19599424 MAIL ADDRESS: STREET 1: C/O REGULUS THERAPEUTICS INC. STREET 2: 3545 JOHN HOPKINS COURT SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TCR2 THERAPEUTICS INC. CENTRAL INDEX KEY: 0001750019 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 474152751 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-949-5200 MAIL ADDRESS: STREET 1: 100 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2019-02-13 0 0001750019 TCR2 THERAPEUTICS INC. TCRR 0001555918 Gibson Neil W TCR2 THERAPEUTICS INC. 100 BINNEY STREET CAMBRIDGE MA 02142 1 0 0 0 Stock Option (Right to Buy) 6.07 2028-12-12 Common Stock 8072 D Series B Preferred Stock Common Stock 706351 I See Footnote 25% of this option shall vest and become exercisable on December 13, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Each share of Series B Preferred Stock is convertible into shares of the Issuer's common stock, par value $0.0001 ("Common Stock") a 6.1938:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Preferred Stock has no expiration date. The shares are held by Curative Ventures CT LLC. The Reporting Person is a partner at Curative Ventures CT LLC and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Exhibit 24.1: Power of Attorney /s/ Neil Gibson 2019-02-13 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT

                               Power of Attorney

   Know all by these presents, that the undersigned hereby constitutes and
appoints each of Margaret Siegel and Stephen Turkowiak, signing singly, and with
full power of substitution, as the undersigned's true and lawful attorney-in-
fact to:

        (1) execute for and on behalf of the undersigned, in the u
        ndersigned's capacity as an officer and/or director of TCR2 Therapeutics
        Inc., a Delaware corporation (the "Company"), from time to time the
        following Securities and Exchange Commission (the "SEC") forms: Forms 3,
        4, and 5 in accordance with Section 16(a) of the Securities Exchange Act
        of 1934, as amended (the "Exchange Act"), and the rules thereunder;

        (2) do and perform any and all acts for and on behalf of the undersigned
        which may be necessary or desirable to complete and execute any such
        Form 3, 4, or 5, complete and execute any amendment or amendments
        thereto, and timely file such form with the SEC and any stock exchange
        or similar authority; and

        (3) take any other action of any type whatsoever in connection with the
        foregoing which, in the opinion of such attorney-in-fact, may be of
        benefit to, in the best interest of, or legally required by, the
        undersigned, it being understood that the documents executed by such
        attorney-in-fact on behalf of the undersigned pursuant to this Power of
        Attorney shall be in such form and shall contain such terms and
        conditions as such attorney-in-fact may approve in such attorney-in-
        fact's discretion.

   The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, is not assuming, nor
is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.

   This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact. This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an officer of
the Company. This Power of Attorney may be filed with the SEC as a confirming
statement of the authority granted herein.

   IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 13th day of February, 2019.

              /s/ Neil Gibson
              ---------------
Printed Name: Neil Gibson